Previous 10 | Next 10 |
Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib Canada NewsWire The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for len...
CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire LEIDEN, The Netherlands , Sept. 7, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief E...
Orchard Therapeutics has become interesting after its 78% dip plus the fact that a large investment fund quadrupled its position in the stock. The company has commercialized gene therapy to combat MDL, which inflicts children. A competitive analysis reveals the strength of the U.K...
Pharming Group N.V. (PHGUF) First Half 2022 Earnings Conference Call August 04, 2022 7:30 AM ET Company Participants Sijmen de Vries – Chief Executive Officer Anurag Relan – Chief Medical Officer Jeroen Wakkerman – Chief Financial Officer ...
The following slide deck was published by Pharming Group N.V. in conjunction with their 2022 Q2 earnings call. For further details see: Pharming Group N.V. 2022 Q2 - Results - Earnings Call Presentation
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency Canada NewsWire Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts ...
A committee of the European Medicines Agency (EMA) granted accelerated assessment for Pharming's ( NASDAQ: PHAR ) potential application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndr...
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS Canada NewsWire EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days ...
Pharming Group N.V. (PHGUF) Q1 2022 Earnings Conference Call May 12, 2022, 07:30 AM ET Company Participants Sijmen de Vries - CEO Jeroen Wakkerman - CFO Anurag Relan - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainright Hartaj Singh - Oppenheimer & Co. Christ...
Pharming Group (NASDAQ:PHAR) said the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to leniolisib to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency disease. The comp...
News, Short Squeeze, Breakout and More Instantly...
2024-05-26 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...